Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors

NCT01302405 | Terminated Phase 1 DMC

• 1 other identifier: PRI-724-101
• Study Type: interventional
• Target: 23
• Locations: 1 country
• Sites: 3

Brief Summary

PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced solid tumors. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and spread(metastasize). Phase Ia: Patient cohorts with solid tumor malignancies will be treated with escalating doses (per cohort) of PRI-724 in order to identify the MTD of this single-agent regimen. PRI-724 dosing is to start at 40 mg/m2/day, CIV infusion over 24 hours × 7 days. Phase Ib: This phase is to begin upon identification of the MTD in Phase 1a. Patient cohorts with CRC will be treated with escalating doses (per cohort) of PRI-724 administered in combination with a modified regimen of FOLFOX6 (mFOLFOX 6, standardized doses and schedule) in order to identify the MTD of this combined regimen. Up to 2 dose levels of PRI-724 are to be examined (640 and 905 mg/m2/day, CIV infusion over 24 hours × 7 days), with potential to evaluate a previously unexamined intermediate dose, if indicated, to more fully characterize tolerability. The MTD cohort (or maximum dose to be studied) will be expanded up to 12 patients.

Conditions

Advanced Solid Tumors

Keywords

Advanced solid tumor; cancer; phase 1; pancreatic cancer; colon cancer; unresectable neoplastic disease; Progressive cancer; metastatic solid tumor

Outcome Measures

Primary Outcomes (1)

• Maximum Therapeutic Dose, as defined by the highest dose identified in which ≤1/3 or ≤2/6 patients do not experience a dose limiting toxicity

  Maximum Therapeutic Dose (MTD) will be the highest dose in which no dose limiting toxicity (DLT) is seen in a accelerated enrollment cohort (1 patient) and then subsequently a 3-6 patient cohort following a 3+3 study design. MTD may also be determined by evaluation of PK and PD results of patients.

  Assessed at the completion of each patient enrollment cohort. Each patient monitoring duration is 28 days.

Secondary Outcomes (1)

• Maximum Therapeutic Dose of combined regimen, as defined by the highest dose identified in which ≤1/3 or ≤2/6 patients do not experience a dose limiting toxicity

  Assessed at the completion of each patient enrollment cohort. Each patient monitoring duration is 28 days

Study Arms (1)

PRI-724

EXPERIMENTAL

Drug: PRI-724

Interventions

PRI-724 DRUG

Dose escalation

PRI-724

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must fulfill all of the following criteria:
• In the dose-escalation part of the study (Phase Ia), patients mu have histological or cytological evidence of solid tumor malignancy; in the tumor-specific, dose-escalation/MTD-expansion part of the study (Phase Ib), patients must have histological or cytological evidence of colorectal cancer.
• Patients must have neoplastic disease that is metastatic or unresectable, that has recurred or progressed following standard therapy, not be candidates for standard therapy, or have a malignancy for which no standard therapy exists. In Phase Ib,patients must have colorectal cancer with tumor sites safely accessible for biopsy, and they must have measurable disease according to the response evaluation criteria in solid tumors (RECIST 1.1) criteria.
• In Phase Ib patients must have received and either relapsed from or failed at least two but no more than three prior regimens of chemotherapy, and be eligible to receive third- or fourth-line therapy for their malignancy.
• Patients must agree, as part of the informed consent, to provide blood samples for molecular correlative studies. In the Phase Ib cohorts, patients must agree to pre- and post-treatment biopsies of their malignant disease.
• Patients must be \> 18 years of age.
• Patients must have a Karnofsky Performance Score of 70% - 100%.
• Patients must have a life expectancy of at least 12 weeks.
• Patients or their legal representatives must be able to comprehend and provide written informed consent.
• Patients must have adequate bone marrow reserve as evidenced by:
• White blood cell (WBC) count\> 3,000/µL
• Absolute neutrophil count (ANC) \> 1,500/µL - Platelet count\> 100,000/µL
• Patients must have adequate renal function as evidenced by a serum creatinine value less than the upper limit of normal (\< ULN) for the reference lab or creatinine clearance (CrCl) of \> 60 mL/min (as calculated by Cockcroft-Gault formula).
• Patients must have adequate hepatic function as evidenced by a serum bilirubin \< 1.5 mg/dL and serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels \< 3X the ULN for the reference lab (\< 5X the ULN if there is evidence of hepatic involvement by malignant disease).
• Patients must be recovered to Grade 1 from the effects (excluding alopecia) of any prior therapy for their malignancies. In Phase Ib patients must have no peripheral sensory neuropathy \> Grade 1.

You may not qualify if:

• Patients exhibiting any of the following will be excluded from the trial:
• Infection requiring systemic antibiotics 72 hours prior to the first dose of PRI-724.
• Known hypersensitivity to any of the components of PRI-724.
• Women who are pregnant or lactating.
• Untreated central nervous system (CNS) metastases; patients whose CNS metastases have been treated by surgery or radiotherapy, who are no longer on corticosteroids, and who are neurologically stable may be enrolled in the initial dose escalation portion of the trial (Phase Ia), but not in the Phase Ib portion of the trial.
• Treatment with any investigational agent within a period of 28 days between the last dose of the investigational agent and the first dose of PRI-724.
• QTcF intervals \> 470 msec (females) or \> 450 msec (males).
• Active hepatitis B, hepatitis C.
• New York Heart Association (NYHA) Class 3 or 4; myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months; or any other intercurrent medical condition that contra-indicates treatment with PRI-724 or places the patient at undue risk for treatment-related complications.
• Any other condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.
• Patients with a current condition of osteopenia or osteoporosis via a Dual Energy X-ray Absorptiometry (DEXA) scan; patients with a history of either are allowed.
• Patients on any dose of warfarin are excluded.
• Given the potential interaction between C82, the metabolite of PRI-724, and CYP3A4 inhibitors, treating physicians should exercise caution and switch patients to equivalent drugs that are not potent CYP3A4 inhibitors when feasible. Medications which are sensitive substrates of CYP2C9 or CYP3A4 with a narrow therapeutic range should be used with caution.
• In Phase 1b, patients with a history of poor FOLFOX tolerability as manifested by inability to tolerate standard therapeutic doses (i.e., at minimum patients must have tolerated an oxaliplatin dose of 85 mg/m2 and a 5FU dose of 2400 mg/m2).
• Note: Patients are eligible for this trial if, during the previous FOLFOX administration, they underwent one dose reduction of oxaliplatin due to sensory neuropathy (provided the neuropathy has now resolved to Grade 1 or less), and/or one dose reduction of 5FU due to cumulative toxicity.

Sponsors & Collaborators

• Prism Pharma Co., Ltd.: lead
• inVentiv Health Clinical: collaborator

Study Sites (3)

Mayo Clinic

Scottsdale, Arizona, 85259-5499, United States

Location

University of Southern California, Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

Location

Mayo Clinic, Department of Oncology

Rochester, Minnesota, 55901, United States

Location

MeSH Terms

Conditions

Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Neoplasm Metastasis

Interventions

ICG 001

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases; Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Anthony El-Khoueiry, MD

  University of Southern California

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 18, 2011
• First Posted: February 24, 2011
• Study Start: February 1, 2011
• Primary Completion: January 1, 2015
• Study Completion: June 1, 2015
• Last Updated: August 17, 2017

Record last verified: 2015-10

Locations

US (3)